The Alzheimer’s Association, the world leader in Alzheimer research, care and support, is the first and largest voluntary health organization dedicated to finding prevention methods, treatments and an eventual cure for Alzheimer’s. Our mission is to eliminate Alzheimer’s disease through the advancement of research; to provide and enhance care and support for all affected; and to reduce the risk of dementia through the promotion of brain health. Our toll-free helpline provides reliable information, referrals and support in 140 languages: 1.800.272.3900.
The mission of the Alzheimer’s Drug Discovery Foundation (ADDF) is to accelerate drug discovery for Alzheimer’s disease, related dementias and cognitive aging. The ADDF funds research projects in academia and biotechnology companies, organizes scientific conferences, convenes key thought leaders, and develops relevant resources towards this goal.
The AACR Foundation accelerates progress by providing financial support for scientific research, education, and communication. The Foundation funds programs deemed by the American Association for Cancer Research to be of the highest priority and impact. The Association’s objectives are to foster research in cancer and related biomedical science; expedite the development of new research findings among scientists and others dedicated to the eradication of cancer; promote science education and training; and advance the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world. Founded in 1907, the Association is the nation’s oldest cancer research organization, currently representing over 34,000 basic scientists, clinicians, epidemiologists, and other oncology-related specialists in the United States and more than 90 countries worldwide.
Founded in 1973, the American Brain Tumor Association was the first and is now the only national organization committed to funding brain tumor research and providing support and education programs for all tumor types and all age groups. Patients are the core of the American Brain Tumor Association’s research funding program. Each grant funded by the ABTA is selected because of the way it supports the organization’s mission of advancing the understanding and treatment of brain tumors with the goals of improving, extending and, ultimately, saving the lives of those impacted by a brain tumor diagnosis. Through the funding of early career scientists, the ABTA is seeding the field with talented young investigators who have the potential to change our understanding of the causes, effects, diagnosis and treatment of brain tumors. The ABTA supports innovative discovery science that is developing new drugs, new imaging techniques, and advanced methods of diagnosing brain tumors; collaborates with other research funders, both in and out of the brain tumor field, to expand the understanding of this disease while learning from other diseases; and supports research that will improve the quality of life of brain tumor survivors and their caregivers.
The American Cancer Society combines an unyielding passion with nearly a century of experience to save lives and end suffering from cancer. As a global grassroots force of more than three million volunteers, we fight for every birthday threatened by every cancer in every community. We save lives by helping people stay well by preventing cancer or detecting it early; helping people get well by being there for them during and after a cancer diagnosis; by finding cures through investment in groundbreaking discovery; and by fighting back by rallying lawmakers to pass laws to defeat cancer and by rallying communities worldwide to join the fight. As the nation’s largest non-governmental investor in cancer research, contributing over $4.0 billion, we turn what we know about cancer into what we do. As a result, about 11 million people in America who have had cancer and countless more who have avoided it will be celebrating birthdays this year. To learn more about us or to get help, call us any time, day or night, at 1-800-227-2345 or visit cancer.org.
The American Diabetes Association is the nation’s leading nonprofit health organization providing diabetes research, information and advocacy. Founded in 1940, the American Diabetes Association conducts programs in all 50 states and the District of Columbia, reaching hundreds of communities. The mission of the Association is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. To fulfill this mission, the American Diabetes Association funds research, publishes scientific findings, provides information and other services to people with diabetes, their families, health professionals and the public. The Association is also actively involved in advocating for scientific research and for the rights of people with diabetes.
The American Epilepsy Society is one of the oldest neurological professional organizations in this country, with members including clinicians, scientists investigating basic and clinical aspects of epilepsy, and other professionals interested in seizure disorders. The mission of the American Epilepsy Society is to advance research and education for professionals dedicated to the prevention, treatment and cure of epilepsy.
The American Federation for Aging Research (AFAR) is a leading, not-for-profit organization supporting biomedical aging research. Since 1981, AFAR has awarded approximately $124 million to more than 2,600 talented scientists. The important work AFAR supports leads to a better understanding of aging processes and to improvements in the health of all people as they age.
The American Heart Association (AHA) is a national voluntary health agency dedicated to building healthier lives, free of cardiovascular diseases and stroke. The American Stroke Association is a division of the American Heart Association. The association’s 2020 health impact goal is to improve the cardiovascular health of all Americans by twenty percent while reducing deaths from cardiovascular diseases and stroke by twenty percent. To accomplish this, the association strives to raise public awareness about healthy lifestyles, enhance the focus of prevention among healthcare providers, as well as provide funding to research programs that will enrich the existing pool of evidence-based research and identify new ways to prevent, detect and treat cardiovascular disease and stroke. The American Heart Association includes the National Center (located in Dallas, Texas) and seven affiliates’ offices that cover across the United States and Puerto Rico.
The Arnold and Mabel Beckman Foundation provides grants to researchers and non-profit research institutions in chemistry and life sciences to promote scientific discoveries, and particularly to foster the invention of methods, instruments, and materials that will open up new avenues of research.
The Arthritis Foundation (www.arthritis.org) is the largest and most trusted nonprofit organization dedicated to addressing the needs and challenges of those living with arthritis, the nation’s leading cause of disability. Since 1948, the Foundation has remained committed to leading groundbreaking research for better treatments and a cure; fighting for patients’ access to affordable and effective health care; and providing trusted information and resources to the more than 50 million adults and 300,000 children living with the disease.
The Arthritis National Research Foundation (ANRF) is the only charity solely dedicated to funding research to cure arthritis. Arthritis is the leading cause of disability in the U.S., affecting 52 million adults and 300,000 children. To find a cure, ANRF funds newer, cutting-edge scientists conducting arthritis research at nonprofit institutions across America. These scientists are the best of the best, but need funding to test their novel ideas. ANRF gives these MD and/or PhD researchers the financial boost they need to test these innovative ideas. Over 250 top young scientists have been funded by ANRF since 1970. Grants awards are a maximum of $100,000 per year.
ANRF has received Charity Navigator’s highest 4-star rating for seven consecutive years, something only 2 percent of U.S. charities can claim.
Founded in 2009, the Autism Science Foundation’s (ASF) mission is to support autism research by providing funding and other assistance to scientists and organizations conducting, facilitating, publicizing, disseminating and providing training for autism research. Through multiple mechanisms, ASF supports research into the risk factors, diagnosis, intervention, treatments, and services for autism spectrum disorders. To date, the foundation has provided $2 million in support to autism research. In addition, ASF heavily promotes participation in research and educates the community on the ways to do so. The organization also provides information about autism, and the science of autism, to the general public and serves to increase awareness of autism spectrum disorders and the needs of individuals and families affected by autism.
At Autism Speaks, our goal is to change the future for all who struggle with autism spectrum disorders. We are dedicated to funding global biomedical research into the causes, prevention, treatments, and cure for autism; to raising public awareness about autism and its effects on individuals, families, and society; and to bringing hope to all who deal with the hardships of this disorder. We are committed to raising the funds necessary to support these goals. Autism Speaks aims to bring the autism community together as one strong voice to urge the government and private sector to listen to our concerns and take action to address this urgent global health crisis. It is our firm belief that, working together, we will find the missing pieces of the puzzle. Autism Speaks. It’s time to listen.
The Avon Foundation for Women has been improving and saving women’s lives since it was founded in 1955, and we are proud to be the largest corporate-affiliated philanthropy dedicated to women’s causes globally. Today our mission is focused on breast cancer and domestic violence, as well as emergency and disaster relief, touching lives across the country and around the world. The Avon Breast Cancer Crusade was launched in 1992 and over the last 18 years, Avon philanthropy has raised and donated almost $700 million to breast cancer programs around the world. Our funds support cutting-edge research to understand the causes of and to develop new ways to prevent breast cancer as well as programs that enable all patients to access quality screening and care. Beneficiaries of the Avon Breast Cancer Crusade range from leading cancer research and clinical centers to community-based, non-profit breast health education programs.
The Bladder Cancer Advocacy Network is the first national nonprofit organization devoted to advancing bladder cancer research and supporting those impacted by the disease. Since its founding in 2005, BCAN has been on the front lines advocating for greater public awareness and increased funding for research to develop better treatments and a cure for bladder cancer.
The Bonnie J. Addario Lung Cancer Foundation (ALCF) is one of the largest philanthropies (patient-founded, patient-focused, and patient-driven) devoted exclusively to eradicating Lung Cancer through research, early detection, education, and treatment. The Foundation’s goal is to work with a diverse group of physicians, organizations, industry partners, individuals, patients, survivors, and their families to identify solutions and make timely and meaningful change and turn lung cancer into a chronically managed disease by 2023. The ALCF was established on March 1, 2006 as a 501c(3) non-profit organization and has raised nearly $30 million for lung cancer research and related programs. For more information about the ALCF please visit www.lungcancerfoundation.org or follow us on Facebook or Twitter.
The Breast Cancer Research Foundation (BCRF) advances the world’s most promising research to eradicate breast cancer. Founded by Evelyn H. Lauder in 1993, BCRF has raised more than $480 million to date to support stellar investigators across the globe who are conducting the most advanced and promising breast cancer research. Since BCRF’s inception, talented scientists have used BCRF grants to test new concepts and pilot innovative investigations, as well as to initiate much-needed correlative science activities not eligible for industry support or federal grants. BCRF not only offers established investigators the flexibility to pursue new inquiries and complementary research activities, but it is equally dedicated to training the next generation of innovators and leaders in the field. This year, BCRF invested $45 million in the work of more than 200 researchers at leading medical institutions across six continents, to support innovative studies aimed at breast cancer prevention and cure. BCRF’s portfolio aims to advance knowledge on cancer biology, develop novel targeted therapies to yield greater patient benefits, and create new diagnostic and prognostic tools. Its talented investigators have made landmark achievements, uncovering crucial insights into the nature of breast cancer, and improving survival and quality of life. Following Evelyn Lauder’s death in 2011, BCRF established the Evelyn H. Lauder Founder’s Fund, dedicated to a multi-year global collaborative program to understand the molecular mechanisms of metastasis, cancer’s ability to spread from the breast to other parts of the body. The Founder’s Fund is committing more than $25 million over the next three to five years to coordinate the efforts of leading clinical and laboratory sites across North America and Europe and will identify molecular abnormalities underlying metastasis, follow individual patients to see how their metastases change over time, and undertake comprehensive analyses of the effects of treatments which target the specific abnormalities. By spending 91 cents of every dollar on research and public awareness, BCRF remains one of the nation’s most fiscally responsible charities. We are the only breast cancer organization with an “A+” from CharityWatch, and have been awarded a 4-star rating from Charity Navigator 12 times since 2002.
BrightFocus Foundation (www.brightfocus.org) is a nonprofit organization that seeks to save mind and sight, by funding innovative research worldwide on Alzheimer’s disease, macular degeneration, and glaucoma. Since inception, the organization has awarded more than 1,000 research grants for a total of $140 million, including more than $35 million in the last five years alone. BrightFocus also promotes better health through education, providing the public with information about these diseases, including risk factors, detection, current treatments, and coping strategies.
The Burroughs Wellcome Fund is an independent private foundation dedicated to advancing the medical sciences by supporting research and other scientific and educational activities. Within this broad mandate, BWF’s general strategy is to help scientists early in their careers develop as independent investigators and to support investigators who are working in or entering fields in the basic medical sciences that are undervalued or in need of encouragement. We channel our financial support primarily through competitive peer-reviewed award programs, which encompass five major categories: basic biomedical sciences, infectious diseases, interfaces in science, translational research, and science education. BWF makes approximately $35 million in grants annually to institutions in the United States and Canada.
Since its inception in 1953, the Cancer Research Institute (CRI) has had a singular mission—to foster research that will yield an understanding of the immune system and its response to cancer, with the ultimate goal of developing immunological methods for the treatment, control, and prevention of the disease. To accomplish this, CRI funds and coordinates an international network of laboratory and clinical research scientists working within the fields of immunology and tumor immunology. Through integration of basic and clinical research initiatives, CRI is accelerating the discovery, testing, and optimization of next-generation cancer immunotherapies such as cancer vaccines and antibodies. The Cancer Research Institute identifies top scientific talent through the guidance of the CRI Scientific Advisory Council (SAC), an international roster of leaders in the field of immunology who support CRI’s efforts to foster creative, scientifically rigorous research. The SAC counts among its members three Nobel Laureates, 31 members of the National Academy of Sciences, and 24 members of the Academy of Cancer Immunology.
The Children’s Tumor Foundation was founded in 1978 and funds research focused on finding effective treatments for the millions of people worldwide living with neurofibromatosis (NF), a term for three distinct disorders: NF1, NF2, and schwannomatosis. NF can cause tumors to grow on nerves throughout the body and may lead to blindness, bone abnormalities, cancer, deafness, disfigurement, learning disabilities, and excruciating and disabling pain. NF affects one in every 3,000 people, more than cystic fibrosis, Duchenne muscular dystrophy, and Huntington’s disease combined. The Children’s Tumor Foundation’s research benefits those who live with NF and also sheds light on several forms of cancer, brain tumors, bone abnormalities, and learning disabilities, ultimately benefiting the broader community. There is currently no effectual treatment for neurofibromatosis, so CTF supports NF research from bench-to-bedside:
- Young Investigator Awards: Two year postdoctoral funding
- Drug Discovery Initiatives (DDI): Seed grants for preclinical screening of candidate NF treatments
- The NF Therapeutic Consortium: A multi-year, multi-center program to accelerate the identification of effective drug therapies.
- The NF Clinic Network: In 44 locations nationwide, established to standardize and improve NF clinical care in the U.S., and to integrate it with NF research.
- Clinical Research Awards: CRAs offer funding to test a drug in a small group of patients or to develop clinical trial enabling tools such as imaging or biomarkers.
- Synodos: A first-of-its-kind NF research collaboration dedicated to defeating NF2 through the sharing of information, datasets, results, and more at every step in the drug discovery process.
The Conquer Cancer Foundation advances breakthrough cancer research and shares new discoveries and expanded knowledge about cancer with doctors, patients, and families worldwide. We support a wide range of research initiatives designed to provide insight into virtually every aspect of cancer, from prevention and diagnosis to treatment and survivorship. We place special emphasis on funding the work of promising young scientists – helping to launch their careers and build the future of cancer research. We help to ensure that all people have access to high-quality cancer care by supporting training opportunities for doctors and by funding research to gain insight into health care disparities. We support the educational and advocacy work of our affiliate, the American Society of Clinical Oncology (ASCO) – and we channel the expertise of the Society’s more than 30,000 members in support of our mission. We help to keep doctors, patients, and families informed by supporting the development of an array of educational resources, including ASCO’s award-winning website, Cancer.Net.
Citizens United for Research in Epilepsy (CURE) is the leading nongovernmental agency fully committed to funding research in the epilepsies. CURE is at the forefront of epilepsy research, raising millions to fund innovative research and other initiatives that will lead the way to a cure. CURE’s transformative research program has supported more than 160 brilliant scientists and labs in 13 countries. Since its inception in 1998, CURE has raised more than $26 million for research program activities. CURE invests more than 89% of its funds in its mission, among the highest percentage for charities nationwide.
The Damon Runyon Cancer Research Foundation provides exceptional early career scientists with funding to pursue innovative ideas in cancer treatment, prevention, and diagnosis. Damon Runyon funds a broad spectrum of basic and translational research relevant to all forms of cancer through its prestigious scientific award programs: the Damon Runyon Fellowship and Damon Runyon-Sohn Pediatric Cancer Fellowship Awards for exceptional postdoctoral fellows, the Damon Runyon-Rachleff Innovation Award for new independent researchers with bold ideas that have the potential to transform cancer prevention and treatment, and the Damon Runyon Clinical Investigator Award for early career physician-scientists committed to moving scientific discoveries from the lab to patients. Since its founding in 1946, Damon Runyon has invested nearly $275 million in cancer research and funded more than 3,420 scientists, including 12 Nobel Laureates.
The Patrick and Catherine Weldon Donaghue Medical Research Foundation works to be an imaginative, collaborative and engaged partner in health research that provides practical benefit to improve health. Donaghue is particularly interested in funding research that has the potential for direct, near-term impact to improve health and in supporting initiatives designed to promote the transfer of knowledge to useful applications. From a gift of $53 million from Ethel Donaghue in memory of her parents, Donaghue has provided $87 million in research grants.
Established in 1996, the mission of the Doris Duke Charitable Foundation is to improve the quality of people’s lives through grants supporting the performing arts, environmental conservation, medical research and child well-being, and through preservation of the cultural and environmental legacy of Doris Duke’s properties. The mission of the Medical Research Program is to advance the prevention, diagnosis and treatment of human diseases by strengthening and supporting clinical research. This mission is carried out through grant programs that foster the career development of outstanding young investigators; that encourage innovative approaches to clinical research in targeted disease areas, most recently sickle cell disease; and that nurture research careers among high school and medical school students. In keeping with the wishes expressed in Doris Duke’s will, the Medical Research Program does not fund research that uses animals.
The Flinn Foundation is a private philanthropic trust created in 1965 by Dr. and Mrs. Robert S. Flinn to improve the quality of life in Arizona. The Phoenix-based Foundation supports the advancement of the biosciences in Arizona, including precision medicine, translational research, and building collaborative research programs between Arizona medical schools and clinical centers. The Foundation also supports a major college scholarship program at Arizona’s public universities, an initiative to advance the critical role of arts and culture in Arizona’s communities, an a program to strengthen civic leadership and develop future state-level leaders in Arizona.
The Focused Ultrasound Foundation is a medical technology research, education and advocacy organization created to improve the lives of millions of people with serious medical disorders by accelerating the development and adoption of focused ultrasound. The Foundation works to clear the path to global adoption by coordinating and funding research and educational activities, fostering collaboration among stakeholders, and building awareness of the technology among patients and professionals. The Foundation is dedicated to ensuring that focused ultrasound finds its place as a mainstream therapy for a range of neurological disorders, including Parkinson’s disease, brain tumors and epilepsy as well as uterine fibroids, cancer and other life-threatening conditions within years, not decades. Since its establishment in 2006, the Foundation has become the largest non-governmental source of funding for focused ultrasound research.
Fondation Leducq, based in Paris, France, is dedicated to improving human health through international efforts to combat cardiovascular disease. With a Scientific Advisory Committee made up of leading medical experts from Europe and North America, the foundation has made collaborative research in cardiovascular and neurovascular disease the focus of its grant program, the Transatlantic Networks of Excellence. With this program the Leducq Foundation supports teams of scientists, comprised of European and North American investigators, who work together to solve some of the most difficult problems in cardiovascular research. It is hoped that through their joint efforts we will advance our knowledge of, and ability to treat, one of the leading causes of death and disability in the industrialized as well as the developing world.
The urgent mission of the Foundation Fighting Blindness is to drive the research that will provide preventions, treatments and cures for people affected by retinitis pigmentosa, macular degeneration, Usher syndrome and the entire spectrum of retinal degenerative diseases. Since its establishment in 1971, the Foundation has raised nearly $550 million to fund thousands of studies at hundreds of prominent institutions. Throughout its history, FFB has maintained an extraordinary commitment to directing as much revenue as possible for research and public health education programs – historically, more than 75 percent. . This has made FFB the world’s leading non-governmental source for inherited retinal disease research funding. FFB-funded investigators are exploring a variety of areas including: genetic discovery, gene therapy, cellular transplantation, drug development, nutrition and retinal prosthetics. The Foundation’s Scientific Advisory Board – leaders in retinal disease science and clinical care – provide oversight and guidance. FFB also established the –Foundation Fighting Blindness Clinical Research Institute to accelerate the translation of laboratory-based research into clinical trials for treatments and cures of retinal degenerative diseases.
The mission of the Foundation for Physical Therapy is to fund and publicize research that determines the scientific basis and value of services provided by physical therapists and to develop the next generation of investigators. Established in 1979, the Foundation supports the profession’s research needs in basic science research, clinical research, and health services research. The Foundation has awarded more than $13 million to launch the careers of hundreds of physical therapist scientists who have then leveraged this support to secure an estimated $550 million in additional research funding from other sources. Many of today’s leading physical therapist researchers, clinicians, and academicians began their careers with a grant or scholarship from the Foundation – more than 7,000 publications contributing to the evidence-based practice of physical therapy have been published in peer-reviewed journals by our alumni. We strive to continue to advance the applications of physical therapy and support the emerging scientist.
The Gerber Foundation is an independent, private foundation dedicated to improving the health and nutrition of infants and young children by supporting medical research targeted from pre-birth to 3 years of age. Major categories of focus are general health and chronic disease issues, nutrition, and environmental hazards as they may affect this age group. Within this mandate, the Foundation focuses on translational and clinical research and support for early career development of investigators. The Gerber Foundation awards approximately $3.5 million in grants annually to institutions within the United States.
Founded in 1965 through the philanthropy of Paul F. Glenn, the mission of the Glenn Foundation For Medical Research (“GFMR”) is to extend the healthy years of human life through support of research on mechanisms of biology that govern normal human aging and its related physiological decline, with the objective of translating research into interventions that will extend healthspan with lifespan. The GFMR primarily carries out its mission through the following programs: (i) The Paul F. Glenn Centers for the Biology of Aging Research; (ii) Glenn Awards for Research in the Biological Mechanisms of Aging; and (iii) Glenn/AFAR awards, programs and scholarships. In addition to the foregoing, the GFMR provides support for a number of conferences, workshops, symposia and other educational opportunities for scientists to share information relevant to the mission of the GFMR. This includes an annual multiday workshop organized and hosted by the GFMR.
The Hydrocephalus Association (HA) is working to eliminate the challenges of hydrocephalus and improve the lives of over one million people and families living with this condition. With a national network of over 30 community partners the HA provides support, education, and advocacy to thousands of families each month, and is aggressively executing a new research agenda aimed at improving lives and seeking ways to prevent and/or cure hydrocephalus.
The Iacocca Family Foundation, which was established in 1984, funds innovative and promising type 1 diabetes research programs and projects that will lead to a cure for the disease and alleviate complications caused by it. Since its inception, the Foundation has supported more than $40 million in promising research projects.
JDRF is the leading global organization funding type 1 diabetes (T1D) research. JDRF’s goal is to progressively remove the impact of T1D from people’s lives until we achieve a world without T1D. JDRF collaborates with a wide spectrum of partners and is the only organization with the scientific resources, regulatory influence, and a working plan to better treat, prevent, and eventually cure T1D. As the largest charitable supporter of T1D research, JDRF is currently sponsoring $568 million in scientific research in 17 countries. For more information, please visit jdrf.org.
The John Templeton Foundation serves as an international philanthropic catalyst for discoveries relating to the Big Questions of human purpose and ultimate reality. We support basic and applied research on diverse subjects ranging from complexity and evolution, human health and flourishing, positive traits such as creativity, forgiveness, love, and free will, and others. We encourage civil, informed dialogue among scientists, philosophers, and theologians and between such experts and the public at large, for the purposes of definitional clarity and new insights.
Our vision is derived from the late Sir John Templeton’s optimism about the possibility of acquiring “new spiritual information” and from his commitment to rigorous scientific research and related scholarship. The Foundation’s motto, “How little we know, how eager to learn,” exemplifies our support for open-minded inquiry and our hope for advancing human progress through breakthrough discoveries.
The Kavli Foundation is dedicated to advancing science for the benefit of humanity, promoting public understanding of science and the role of scientific research, and supporting scientists and their work. The Foundation focuses on the scientific fields of astrophysics and cosmology, nanoscience, neuroscience and theoretical physics. Its mission is implemented through funding an international program of endowed research Institutes, Kavli Prizes in science, scientific meetings, endowed chair professorships, science communication programs and other initiatives.
The Kenneth Rainin Foundation invests in innovative and collaborative projects to positively impact quality of life for people who suffer from Inflammatory Bowel Disease (IBD). Our Health Program focuses on improving the diagnosis and treatment of IBD, with the ultimate goal of finding a cure. The Foundation employs two primary strategies to accomplish our mission. We offer several grant programs that fund cutting-edge health research projects to research institutions worldwide. Our annual Innovations Symposium brings together collaborative, innovative and creative thinkers to work towards the common goal of curing IBD. The Symposium facilitates connections between researchers from different disciplines and features a panel of keynote speakers and Rainin Foundation grantees. Since 2002 the Rainin Foundation has awarded over $7.5 million to health researchers at some of the finest institutions throughout the United States and abroad. In the next four years, our funding for medical research is projected to dramatically increase to approximately $5.5 million annually, making the Rainin Foundation one of the leading supporters of IBD research.
The Klarman Family Foundation seeks to identify areas of unmet need and to advance solutions to addressing them. We believe passionately in the promise and importance of creative thinking, strategic leadership and strong organizations to help bring about change. Our intention as a Foundation is to help make measurable progress in improving the lives of others. We invest in research efforts to advance understanding of the biological basis of health and illness. The Foundation’s research grants are currently focused on three efforts: the Anorexia Nervosa Genetics Initiative (ANGI), the Klarman Cell Observatory at the Broad Institute, and the Eating Disorders Research Grants Program. As we are continually learning, our specific areas of focus will evolve. Our dedication to applying best practices in philanthropy will remain unchanged.
The Laura and John Arnold Foundation’s (LJAF) core objective is to address our nation’s most pressing and persistent challenges using evidence-based, multi-disciplinary approaches. LJAF strives to create functional solutions that target the root causes, not just the symptoms, of these problems. The solutions must be both scalable nationally and sustainable without permanent philanthropy.
The mission of the Lawrence Ellison Foundation (formerly the Ellison Medical Foundation) is to foster creativity in basic biomedical research. Since its founding in 1997, the Foundation has supported biomedical research through grant programs designed to provide both experienced investigators and newly independent scientists with the opportunity to take risks and pursue bold and innovative research directions. In particular, the Foundation has aimed to stimulate novel and creative research that has rigorous scientific foundations, but is not adequately funded by traditional sources. Over its history, the primary emphasis of the Foundation’s activities has been to support fundamental research to understand how humans and other organisms age and protect themselves from age-associated diseases and disabilities.
The Leona M. and Harry B. Helmsley Charitable Trust aspires to improve lives by supporting exceptional nonprofits and other mission-aligned organizations in the U.S. and around the world in health, selected place-based initiatives, and education and human services. The Trust currently holds more than $5 billion in assets and has committed more than $1 billion since it began active grantmaking in late 2008. With approximately 70% of its grants focused on health, the Trust currently is the largest private funder in the areas of type 1 diabetes, IBD and Crohn’s Disease, and the provision of rural eHealth services. In addition the Trust supports innovative basic medical research in genomics, stem cells and other areas, as well as a range of medical institutions.
The Leukemia & Lymphoma Society (LLS) exists to find cures and ensure access to treatments for blood cancer patients. LLS’s mission: Cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families. Over the past 65 years, LLS has invested more than $1 billion for research specifically targeting blood cancers through its grants programs and more recently, the Therapy Acceleration Program (TAP). LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care.
LLS is headquartered in White Plains, NY and has chapters throughout the United States and Canada. To learn more visit www.lls.org. Patients should contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 9 p.m. ET.
The Lung Cancer Research Foundation (LCRF) is a nonprofit organization that provides critical funding to innovative research focused on the prevention, diagnosis, and treatment of lung cancer. The LCRF funds projects across the spectrum of basic, clinical, and translational research. To date we have provided more than $18 million through nearly 250 grants for innovative, high-reward lung cancer research that might otherwise go uninvestigated. While lung cancer continues to claim nearly 1.6 million lives each year around the world, we are making significant strides to help conquer this disease by breathing life into research.
LUNGevity is the largest lung cancer-focused organization in the United States. We raise support and awareness from individuals and businesses across the country, with more than 60 annual events in communities throughout the US. The mission of LUNGevity Foundation is to have a meaningful impact on improving lung cancer survival rates, ensure a higher quality of life for lung cancer patients, and provide a community for those impacted by lung cancer. Through the support of critical research into the early detection and successful treatment of lung cancer, as well as providing information, resources and a community to patients and caregivers, LUNGevity is creating and sharing hope for cures, treatments and enhanced quality of life for lung cancer patients. LUNGevity’s vision is a world where no one dies from lung cancer.
The Lupus Foundation of America, Inc. (LFA) is the nation’s foremost national nonprofit voluntary health organization dedicated to finding the causes of and cure for lupus and providing support and services to all people affected by the disease. The LFA manages comprehensive programs of lupus research, education, patient services, and advocacy through a national network of nearly 300 chapters, affiliates, and support groups.
The Lymphoma Research Foundation (LRF) is the nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research and providing people with lymphoma and healthcare professionals with up-to-date information about this type of cancer. LRF’s mission is to eradicate lymphoma and to serve those touched by this disease.
The March of Dimes Foundation is a national voluntary health agency with chapters in all 50 states, the District of Columbia, and Puerto Rico. Its mission is to improve the health of babies by preventing birth defects and infant mortality. The March of Dimes Foundation accomplishes this with its programs of research, community services, education, and advocacy. The organization was established in 1938 by President Franklin D. Roosevelt to lead research efforts on polio, leading to the development of the Salk and Sabin vaccines. This unique collaboration of citizens and scientific researchers was the nation’s first large-scale biomedical initiative led by a charitable organization. Over the years, the March of Dimes Foundation initiatives have helped spare many babies from death or lifelong disability. In 2003, the March of Dimes Foundation launched a multi-year campaign to address the increasing rate of premature birth in the United States.
The Medical Foundation division works with private individuals, bank trusts, and family foundations to design customized grant programs that accelerate medical discoveries. Each year, internationally recognized investigators and physician scientists from across the United States and Europe serve on our eleven Scientific Review Committees. Reviewers provide critical and unbiased evaluations of all applications and research progress reports. Each year, the Medical Foundation’s clients support more than 160 investigators in basic biomedical, translational and clinical research and award close to $16 million. Health Resources in Action (HRiA), the parent organization of The Medical Foundation division, is a nonprofit organization dedicated to advancing public health and medical research.
The Melanoma Research Alliance (MRA) is a 501(c)3 public charity whose mission is to accelerate the pace of scientific discovery and its translation in order to eliminate suffering and death due to melanoma. MRA funds research worldwide to better prevent, diagnose and treat melanoma. Our ultimate goal is to find a cure. Founded in 2007 under the auspices of the Milken Institute with the generous founding support of Debra and Leon Black, MRA has become the largest private funder of melanoma research.
Formed as a result of the 1996 sale of Cleveland’s Mt. Sinai Medical Center and related hospitals, The Mt. Sinai Health Care Foundation is an independent grantmaker affiliated with the Jewish Community of Cleveland. The Foundation’s purpose is to assist Greater Cleveland’s organizations and leaders to improve the health and well-being of the Jewish and general communities now and for generations to come. Among its strategic grantmaking objectives is to advance academic medicine and bioscience, to both expand the bioscience sector of the regional economy and further Cleveland’s prominence in this area. The Foundation’s assets at December 31, 2013, exceeded $150 million.
The Multiple Myeloma Research Foundation (MMRF) was founded by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy was diagnosed with multiple myeloma. The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to extend the lives of patients and lead to a cure. As the world’s number-one private funder of multiple myeloma research, the MMRF has raised over $240 million since its inception to fund more than 340 research grants at 131 institutions worldwide. An outstanding 90% of funds are directed toward research and related programming. The MMRF is currently supporting 53 new compounds and approaches in clinical trials and pre-clinical studies and has initiated 23 clinical trials through its research consortium, the Multiple Myeloma Research Consortium (MMRC).
The Myotonic Dystrophy Foundation (MDF) is the world’s largest patient organization focused solely on Myotonic dystrophy. Our mission, “Care and a Cure,” is to enhance the quality of life of people living with myotonic dystrophy (DM) and advance research focused on treatments and a cure. Past research efforts include awarding annual post-doctoral fellowships, support for the first-ever DM clinical research network and other grants to accelerate DM research. MDF also launched and manages the Myotonic Dystrophy Family Registry, an online, patient-entered database that collects information on disease symptoms, demographic information and quality of life. The Registry supports clinical trials and research studies, and helps drive advocacy efforts focused on improving the circumstances of people living with DM. In addition, MDF has recently committed to a strategic, three year $4.5M-plus plan to accelerate the development of therapies for myotonic dystrophy. The plan draws upon strategies such as de-risking drug development, and creating value and payer advocacy.
Founded in 1968, the National Psoriasis Foundation (NPF) is the world’s largest nonprofit serving people with psoriasis and psoriatic arthritis. Our priority is to provide individuals with the information and services they need to take control of their condition, while increasing research to find a cure. In addition to serving more than 2.1 million people annually through our patient and professional health education and advocacy programs, the NPF is the largest charitable funder of psoriatic disease research worldwide.
The New York Stem Cell Foundation (NYSCF) is a non-profit organization whose mission is to accelerate cures for the major diseases of our time through stem cell research. Our programs are focused in four areas:
- NYSCF Research – Supporting and enabling the unrestricted pursuit of the most advanced stem cell research, both in our own laboratory and through collaborations with major medical research institutions.
- NYSCF Postdoctoral Fellowship Program and Investigator Awards – Supporting and training the next generation of scientists, both at the postdoctoral level as Fellows, and as Early Career Investigators pursuing innovative translational stem cell research in their own laboratories.
- NYSCF Conference and Symposia – Convening the preeminent annual translational stem cell research conference and an on-going series of programs for scientists, policymakers, and the public.
- NYSCF – Robertson Prize – Honoring the most significant achievement in stem cell research each year by a scientist under the age of 40.
The Pancreatic Cancer Action Network is the national organization creating hope in a comprehensive way through research, patient support, community outreach and advocacy for a cure. The organization raises money for direct private funding of research—and advocates for more aggressive federal research funding of medical breakthroughs in prevention, diagnosis and treatment of pancreatic cancer.
The Pancreatic Cancer Action Network fills the void of information and options by giving patients and caregivers reliable, personalized information they need to make informed decisions. The organization helps support individuals and communities all across the country work together to raise awareness and funds to find a cure for pancreatic cancer. We create a sense of hope and community so no one has to face pancreatic cancer alone.
The Parkinson’s Disease Foundation® (PDF®) is a leading national presence in Parkinson’s disease research, education and public advocacy. Since its founding in 1957, PDF has funded over $85 million worth of scientific research, supporting the work of leading scientists throughout the world, and over $34 million to support people living with Parkinson’s through our education and advocacy programs. In addition to supporting teams of researchers in their quest to understand Parkinson’s and find a cure, an important component of PDF’s research focus is addressing the barriers to the acceleration of clinical research – beginning with the training of young neurologists who are needed to conduct clinical research; supporting the collaborative initiatives among the largest group of Parkinson’s clinical researchers in the US; and creating a network of more than 100 research advocates from 36 states who are working to bring educated consumer voices to important issues in Parkinson’s therapy development.
The Patient-Centered Outcomes Research Institute (PCORI) is authorized by Congress to conduct research to provide information about the best-available evidence to help patients and their health care providers make better-informed health and healthcare decisions. PCORI’s research, which is guided by input from stakeholders across the healthcare community, is intended to give patients and those who care for them with a better understanding of the prevention, treatment and care options available, and the science that supports those options. PCORI is committed to improving health by substantially increasing the quantity, quality, and timeliness of useful, trustworthy information available to support health decisions; speeding the implementation of patient-centered knowledge into practice; and influencing clinical and health care research funded by others to be more patient-centered.
Through a generous commitment of $25 million from the Pershing Square Foundation, the Pershing Square Sohn Cancer Research Alliance has created a prestigious program that will award $1.2 million in its first year to exceptional young scientists in New York City with innovative ideas in the field of cancer research. The Prize winners, selected by a panel of extraordinary leaders in medical research, are encouraged to take risks and pursue bold ideas that will lead to new discoveries and new approaches in cancer research. In the quest for cures, the Prize will accelerate collaboration between academia, industry and the business community and play a catalytic role to secure traction for new ideas with non-profit and for-profit investors.
The Pew Biomedical Programs, part of The Pew Charitable Trusts, include the Pew Scholars Program in the Biomedical Sciences and the Pew Latin American Fellows Program. The Pew Scholars Program in the Biomedical Sciences provides $240,000 in funding over four years to young investigators of outstanding promise in science relevant to the advancement of human health who are in their first few years of their appointment at the assistant professor level. The funds may be used, at the discretion of the Pew Scholar, for personnel, equipment, supplies, or travel directly related to the Scholar’s research as to best advance their research and career. The Pew Latin American Fellows Program in the Biomedical Sciences provides support for young scientists from Latin America to receive postdoctoral training in the United States. The Pew Fellowship provides a $30,000 salary stipend in each of two years and an additional $35,000 payment when the Fellow confirms plans to return to Latin America within a maximum of four years from the start date of the grant. The $35,000 portion of the award is for the purchase of supplies and equipment to help establish his/her independent laboratory upon the Fellow’s return to Latin America.
The PSI Foundation was established in 1970 by the physicians of Ontario with the mission of improving the health of Ontarians. PSI is a clinician centered non-profit dedicated to funding physician driven clinically relevant medical research.
The Rheumatology Research Foundation funds groundbreaking research resulting in better care and treatment for more than 50 million Americans affected by rheumatic disease. As the largest private funding source of rheumatology research and training programs in the U.S., the Foundation has awarded over $50 million to more than 1,000 recipients in the past five years. As a result, rheumatologists and health care professionals gain the knowledge and resources to provide their patients with the best possible care.
Based in Princeton, New Jersey, the Rita Allen Foundation was established in 1953 and has for many years sponsored a major grants program for researchers in science and medicine. Our Scholars’ program provides funding to leading medical research institutions selected by a world-class Scientific Advisory Committee. This support allows scientists in the early stages of their careers to innovate and experiment. With our assistance, many Rita Allen Foundation Scholars have made important discoveries and advances. Since 2009, the Rita Allen Foundation has expanded its impact and now invests in other transformative ideas to leverage their growth and promote breakthrough solutions to significant problems. The Rita Allen Foundation’s areas of active interest include investing in young leaders in the sciences and social innovation, promoting civic literacy and engagement, and building stronger communities.
The mission of Sarnoff Cardiovascular Research Foundation is to develop medical students throughout their careers into the next generation of leaders in cardiovascular innovation, research, and medicine by providing mentored research experience and lifelong community.
The mission of the Simons Foundation is to advance the frontiers of research in the basic sciences and mathematics. In the life sciences, institutional and targeted grants support research in systems biology, human evolution and math in biology. The Simons Foundation Autism Research Initiative (SFARI) seeks to understand the causes of autism and thereby improve the diagnosis, treatment, and prevention of this and related developmental disorders. SFARI applications are solicited from individuals who will conduct bold, imaginative, rigorous research relevant to this spectrum of prevalent disorders. The Foundation supports the work of institutions and organizations that give many of the world’s best mathematicians and physicists the opportunity to work and interact in environments designed to enhance progress. Part of our mission is also to train students and educators in these disciplines, and to organize programs that introduce the wonders of these fields to children and to the general public.
The St. Baldrick’s Foundation is a volunteer-driven charity committed to funding the most promising research to find cures for childhood cancers and give survivors long and healthy lives. St. Baldrick’s coordinates its signature head-shaving events worldwide where participants collect pledges to shave their heads in solidarity with kids with cancer, raising money to fund research. Since 2005, St. Baldrick’s has awarded more than $152 million to support lifesaving research, making the Foundation the largest private funder of childhood cancer research grants. St. Baldrick’s funds are granted to some of the most brilliant childhood cancer research experts in the world and to younger professionals who will be the experts of tomorrow. Funds awarded also enable hundreds of local institutions to participate in national pediatric cancer clinical trials, and the new International Scholar grants train researchers to work in developing countries. For more information, please call 1.888.899.BALD or visit www.StBaldricks.org.
Nancy G. Brinker promised her dying sister, Susan G. Komen, she would do everything in her power to end breast cancer forever. In 1982, that promise became Susan G. Komen® and launched the global breast cancer movement. Today, Susan G. Komen is the boldest community fueling the best science and making the biggest impact in the fight against breast cancer. Thanks to events like the Komen Race for the Cure, we have invested almost $2 billion to fulfill our promise, working to end breast cancer in the U.S. and throughout the world through ground-breaking research, community health outreach, advocacy and programs in more than 50 countries. For more information about Susan G. Komen, breast health or breast cancer, visit www.komen.org or call 1-877 GO KOMEN.
The Tuberous Sclerosis Alliance (TS Alliance) is dedicated to finding a cure for tuberous sclerosis complex (TSC) while improving the lives of those affected. TSC is a genetic disorder that causes tumors to form in many different organs, primarily in the brain, eyes, heart, kidney, skin and lungs. Approximately 85 percent of individuals experience seizures during their lifetime, and about one-third of these manifest as infantile spasms, a devastating form of epilepsy occurring in early childhood. Autism occurs in approximately 50 percent of individuals with TSC, and other behavioral and psychiatric symptoms—such as aggression and anxiety—are common. Over 80 percent of individuals with TSC will also develop some form of renal (kidney) disease. The incidence and severity of the various aspects of TSC can vary widely between individuals—even between identical twins. The TS Alliance’s research strategy to accelerate research on TSC focuses on driving collaborative science through five programs: Research Grants, Natural History Database, Biosample Repository, Preclinical Consortium, and Clinical Research Consortium.
The V Foundation’s mission has always been to save lives by finding cures for cancer. The V Foundation funds research in every kind of cancer via three types of grants: The V Scholar Grant, The V Foundation Grants in Translational Cancer Research and Designated Grants. In its first twenty years, the Foundation awarded 540 grants to 122 institutions in 38 states plus DC. Research Proposals are reviewed by The V Foundation’s Scientific Advisory Committee which includes many of the top cancer physicians and scientists from across the country. Grants are ranked through a highly competitive process. Each invited institution submits only one application per year in each category. The V Foundation’s board of directors is comprised of prominent business leaders, award-winning athletes and coaches, distinguished physicians and outstanding journalists and entertainers. Board members serve on a volunteer basis and provide their expertise for the governance of the Foundation.
The W.M. Keck Foundation was established in 1954 in Los Angeles by William Myron Keck, founder of The Superior Oil Company. Following the ideals of its founder, the Keck Foundation’s objective is to support outstanding science, engineering and medical research, undergraduate education, and, in Southern California, community service projects that will have a significant impact in solving complex issues and problems. In the area of biomedical research, the Keck Foundation funds basic research projects proposed by early career and more senior researchers, the development of new scientific instruments and technologies and the establishment of unique laboratories at universities and research institutes. In its Southern California Program the Foundation places special emphasis on children, youth and their families, with the goal of providing safe, healthy, supportive environments. Through this program the Keck Foundation funds health care projects and programs in Southern California hospitals and clinics.
The Weston Brain Institute goal is to accelerate the translation of scientific breakthroughs into safe and effective therapies while using a fast and innovative granting process to provide support to researchers. This initiative continues The W. Garfield Weston Foundation’s long history of supporting medical research. The Weston Brain Institute was established as a new Canadian granting agency to address the existing translational funding gap in neurodegenerative research of the aging population. Our goal is to accelerate the development of therapeutics for neurodegenerative diseases of aging and encourage innovation in the granting process.